1
|
Engesser C, Brantner P, Walter M, Gehweiler J, Seifert H, Subotic S, Rentsch C, Wetterauer C, Bubendorf L, Vlajnic T, Hosseini A, Ebbing J. AURORA a 3D model guided nerve sparing technique in robotic radical prostatectomy. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00525-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
2
|
Garioni M, Blukacz L, Nuciforo S, Roma L, Piscuoglio S, Heim M, Vlajnic T, Seifert H, Bubendorf L, Rentsch C, Le Magnen C. A novel patient-derived model to study cellular plasticity and drug response in sarcomatoid urothelial bladder cancer. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01921-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
3
|
Servant R, Diamantopoulou Z, Garioni M, Roma L, Vlajnic T, Templeton A, Pueschel H, Piscuoglio S, Aceto N, Bubendorf L, Seifert H, Rentsch C, Le Magnen C. Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00502-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
4
|
Servant R, Garioni M, Vlajnic T, Pueschel H, Müller D, Zellweger T, Templeton A, Garofoli A, Maletti S, Diamantopoulou Z, Piscuoglio S, Rubin M, Aceto N, Seifert H, Bubendorf L, Rentsch C, Le Magnen C. Development of novel prostate cancer patient-derived models and applications for translational research. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)01193-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Huang YL, Liang CY, Ritz D, Coelho R, Septiadi D, Estermann M, Rimmer N, Vlajnic T, David L, Rothen-Rutishauser B, Jacob F, Heinzelmann-Schwarz V. Integrin α2-collagen interaction promotes ovarian cancer metastasis. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- Y.-L Huang
- Universitätsspital Basel, Department of Biomedicine
| | - C.-Y Liang
- Universitätsspital Basel, Department of Biomedicine
| | - D Ritz
- Universität Basel, Biozentrum
| | - R Coelho
- University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto
| | - D Septiadi
- University of Fribourg, Adolphe Merkle Institute
| | - M Estermann
- University of Fribourg, Adolphe Merkle Institute
| | - N Rimmer
- Universitätsspital Basel, Department of Biomedicine
| | - T Vlajnic
- Universitätsspital Basel, Institute of Pathology
| | - L David
- University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto
| | | | - F Jacob
- Universitätsspital Basel, Department of Biomedicine
| | - V Heinzelmann-Schwarz
- Universitätsspital Basel, Department of Biomedicine
- Universitätsspital Basel, Gynecological Cancer Center
| |
Collapse
|
6
|
Le Magnen C, Servant R, Vlajnic T, Ruiz C, Zellweger T, Bubendorf L, Seifert HH, Rentsch C. Advancing patient-derived organoids of prostate cancer for disease modeling and personalized medicine. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33821-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Vlajnic T, Savic S, Bubendorf L. ROS1 immunocytochemistry on cytological specimens in patients with non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx090.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
8
|
Vlajnic T, Brady L, Casey O, Gately K, Barr M, Cuffe S, Bubendorf L, Finn S. 26P Characteristics of circulating tumor cells (CTCs) in patients with lung cancer. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30140-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA. Incidental prostate cancer prevalence at radical cystoprostatectomy—importance of the histopathological work-up. Virchows Arch 2014; 465:629-36. [DOI: 10.1007/s00428-014-1656-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 08/25/2014] [Accepted: 09/12/2014] [Indexed: 11/28/2022]
|
10
|
Vlajnic T, Savic S, Bubendorf L. [Pleural mesothelioma. Cytology and molecular diagnostics]. Pathologe 2014; 35:591-6. [PMID: 25069847 DOI: 10.1007/s00292-014-1922-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The definitive diagnosis of malignant mesothelioma (MM) in effusion cytology is often avoided or reluctantly made by cytology alone. The most probable reason for this skepticism is the lack of expertise in cytology among many pathologists and clinicians. When an effusion specimen is composed of cells with unequivocal cytological features of malignancy that have the morphology and immunophenotype of mesothelial cells, the cytological diagnosis of MM is straightforward. However, in the daily routine difficult cases of atypical mesothelial cells are often encountered and additional methods are required to establish an accurate diagnosis. In contrast to reactive mesothelial cells cells of MMs often harbor chromosomal aberrations, most frequently a polysomy in combination with a 9p21 deletion. These chromosomal aberrations can easily be detected by multitarget fluorescence in situ hybridization (FISH); therefore, FISH allows a reliable distinction between reactive mesothelial cells and MM cells. In order to be able to discriminate between MM and adenocarcinoma, an immunocytochemical panel consisting of different mesothelial and epithelial markers is very helpful. In most inconclusive cases of atypical mesothelial cells the combination of morphology, immunocytochemistry and FISH allows a better distinction between reactive mesothelial cells and MM in effusion cytology.
Collapse
Affiliation(s)
- T Vlajnic
- Institut für Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Schweiz,
| | | | | |
Collapse
|
11
|
Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17:126-31. [PMID: 24469092 DOI: 10.1038/pcan.2013.62] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Revised: 12/02/2013] [Accepted: 12/17/2013] [Indexed: 12/21/2022]
Abstract
BACKGROUND Approximately half of the prostate carcinomas are characterized by a chromosomal rearrangement fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS transcription factor ERG. Aim of this study was to comprehensively analyze the role and impact of the ERG rearrangement and protein expression on the progression to castration-resistant (CR) disease. METHODS We used a tissue microarray (TMA) constructed from 114 hormone naive (HN) and 117 CR PCs. We analyzed the ERG rearrangement status by fluorescence in situ hybridization and the expression profiles of ERG, androgen receptor (AR) and the proliferation marker Ki67 by immunohistochemistry. RESULTS Nearly half of the PC tissue specimens (HN: 38%, CR: 46%) harbored a TMPRSS2-ERG gene fusion. HN PCs with positive translocation status showed increased tumor cell proliferation (P<0.05). As expected, TMPRSS2-ERG gene fusion was strongly associated with increased ERG protein expression in HN and CR PCs (both P<0.0001). Remarkably, the study revealed a subgroup (26%) of CR PCs with ERG rearrangement but without any detectable ERG protein expression. This subgroup showed significantly lower levels of AR protein expression and androgen-regulated serum PSA (both P<0.05). CONCLUSIONS In this study, we identified a subgroup of ERG-rearranged CR PCs without detectable ERG protein expression. Our results suggest that this subgroup could represent CR PCs with a dispensed AR pathway. These tumors might represent a thus far unrecognized subset of patients with AR-independent CR PC who may not benefit from conventional therapy directed against the AR pathway.
Collapse
Affiliation(s)
- J R Gsponer
- Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - M Braun
- Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany
| | - V J Scheble
- Institute of Pathology, Comprehensive Cancer Center, University Hospital Tuebingen, Tuebingen, Germany
| | - T Zellweger
- Division of Urology, St Claraspital, Basel, Switzerland
| | - A Bachmann
- Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - S Perner
- Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany
| | - T Vlajnic
- Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - M Srivastava
- Department of Anatomy, Physiology, and Genetics, and Institute for Molecular Medicine, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, MD, USA
| | - S H Tan
- Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - A Dobi
- Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | | | - S Srivastava
- Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - L Bubendorf
- Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - C Ruiz
- Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| |
Collapse
|